logo SBA

ETD

Archivio digitale delle tesi discusse presso l’Università di Pisa

Tesi etd-09172026-161820


Tipo di tesi
Tesi di specializzazione (4 anni)
Autore
MARTELLI, IRENE
URN
etd-09172026-161820
Titolo
Type 2-inflammatory mediators in EGPA: novel potential biomarkers
Dipartimento
MEDICINA CLINICA E SPERIMENTALE
Corso di studi
ALLERGOLOGIA ED IMMUNOLOGIA CLINICA
Relatori
.
relatore Prof.ssa Puxeddu, Ilaria
Parole chiave
  • Alarmins
  • Biological therapy
  • Chemokines
  • Eosinophilic granulomatosis with polyangiitis
  • Type 2 inflammation
Data inizio appello
05/11/2026
Consultabilità
Completa
Riassunto (Inglese)
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune disease characterized by eosinophilic inflammation, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and necrotizing vasculitis of small/medium-sized blood vessels. EGPA is classified among ANCA-associated vasculitis (AAV) however, myeloperoxidase (MPO)-ANCA antibodies are detectable in only about one-third of patients. While ANCA-negative phenotype is mainly characterized by eosinophil-driven manifestations, the ANCA-positive ones are mainly associated with vasculitic manifestations, including mononeuritis multiplex and pauci-immune glomerulonephritis. The introduction in EGPA treatment of mepolizumab, a monoclonal antibody targeting IL-5, at dosage of 300 mg every 4 weeks, has significantly improved the management of the disease by reducing peripheral eosinophilia and improving disease control. Nevertheless, monitoring disease activity remains challenging, as currently available clinical and biological markers partly reflect the complexity of the immunological pathways underlying EGPA. Several studies have suggested that cells and mediators involved in Type-2 inflammation, including alarmins and chemokines, may reflect disease activity in EGPA. Among eosinophil-regulating chemokines, CCL26, fundamental for the recruitment of eosinophils into the tissue, has been associated with active EGPA. Among alarmins, IL-25 together with IL-33 and TSLP, all produced by activated epithelium and acting mainly on Innate Lymphoid Cells type 2 (ILC2), seems to be involved in EGPA at various levels and with different roles. However, the role of these mediators in the development of EGPA remains unclear, and how these mediators might be regulated by new therapeutic approaches has yet to be fully explored. Therefore, the objectives of this study were to evaluate the potential role of epithelial alarmins and eosinophil-related chemokines in different phenotypes of EGPA patients and to assess longitudinal changes in these mediators during treatment with mepolizumab. A further aim of the study was to investigate the associations between these mediators and clinical and biological parameters of the disease. The study included 23 patients enrolled at the Immuno-allergology and Rheumatology Units of Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, with a diagnosis of EGPA, classified according to ACR/EULAR 2022 classification criteria and considered eligible for biological therapy with mepolizumab. All patients underwent a multidisciplinary workup, including evaluations by ENT, pulmonologist, gastroenterologist or haematologist when needed. Demographic and clinical data were recorded at baseline (T0) and after 6 months (T1) and 12 months (T2) of mepolizumab treatment. Eosinophil-regulating chemokines (CCL11, CCL24, CCL26, RANTES) and alarmins (TSLP and IL-25) were evaluated in the peripheral blood of all the patients at different time points and according to the different phenotypes of the disease, specifically based on their atopic status and ANCA positivity. In the cohort of EGPA patients evaluated in the present study, analysis of the chemokines that regulate eosinophil recruitment revealed that CCL26, mainly produced by the epithelium, is significantly reduced in the peripheral blood of EGPA patients at baseline, supporting its potential locally involvement in EGPA rather than in circulation, as occurred in other type-2 driven diseases. Among the alarmins evaluated, IL-25, but not TSLP, was able to discriminate atopic versus non-atopic patients, supporting a potential role of this alarmin in defining a certain phenotype of the disease. Following all the EGPA patients during 12 months of mepolizumab treatment allowed us to confirm in real-life the effectiveness of this therapeutic approach in controlling the disease with a high safety profile. Consistent with the literature, we observed a relevant improvement in asthma symptoms, as shown by ACT and FEV1 parameters, as well as in nasal and paranasal symptoms, as proved by a reduction in NPS and SNOT-22 and an improvement in olfactory function. As expected, we registered a decrease in eosinophil count in the peripheral blood within 6 months. Moreover, mepolizumab treatment was able to drastically reduce OCS-treated patients from 82.6% to 23.5%, without relapse of EGPA. In addition, with observed 78.9% and 94.1% of patients achieving remission at 6 and 12 months, respectively, defined as BVAS = 0 and a prednisone-equivalent dose ≤ 4 mg/day. However, blocking the IL-5 axis does not affect IL-25, which remains an upstream mediator in the type 2 inflammation of EGPA, as well as CCL-26, mainly involved in the local compartment. Identifying type 2 mediators associated with disease activity and clinical phenotypes in EGPA may improve disease monitoring and contribute to better characterize the endotypes of the disease. Further studies are needed to better characterize the tight regulation of type 2 inflammation in EGPA and the potential link between type 2 inflammatory parameters and the activation of the adaptive immune system.
In conclusion, our data confirm, in a real-life setting, the efficacy of mepolizumab 300 mg every 4 weeks in controlling the type 2-dependent features of EGPA and suggest that IL-5 blockade leaves the upstream alarmin signalling unaffected. IL-25 emerged as a potential biomarker of the atopic endotype of EGPA, whereas CCL26 appears to act mainly at the tissue level. Larger, multicentre longitudinal studies are needed to validate these findings and to better define the endotypes of EGPA.
Riassunto (Italiano)
File